Pfizer is suing Poland for 6 billion zloty over 60 million undelivered COVID-19 vaccines, sparking a major legal battle with political and financial implications.
Dispute Details and Legal Basis
Interest, court costs, and litigation fees are added to the base amount (notes indicated a limit of 22.5 thousand euros). The dispute is based on Belgian law, as this is how EU framework contracts were structured. Although formally it concerns the vaccine contract, in practice it affects Poland’s financial policy, relations with the European Commission, and the long shadow of “Pfizergate,” referring to questions about transparency in EU negotiations with the manufacturer.
Refusal of Vaccine Deliveries
The trigger point is the events of April 12, 2022, when Poland’s Ministry of Health informed Pfizer and the EU Commissioner that it would not accept further vaccine deliveries. This was not due to disputes about vaccine effectiveness, as experts agreed the vaccines had saved millions of lives. The problem was oversupply and the risk that further deliveries would end up being disposed of.
Refusal to accept delivery meant the effective termination of the May 2021 contract signed by Poland as part of the EU joint procurement mechanism. The scale of the contracts was unprecedented: originally, 900 million doses were mentioned (plus an option for another 900 million), and ultimately 1.1 billion doses were contracted for a value of over 21 billion euros (about 90 billion zloty).
Pfizer’s Lawsuit and Poland’s Defense
In 2023, Pfizer and its production partner BioNTech decided to sue Poland, demanding 5.65 billion zloty for 60 million undelivered doses. Added to this are interest, court costs, and litigation fees (with a limit of 22.5 thousand euros). In public discourse, the amount is most often rounded to about 6 billion zloty and functions as such in political and media debate.
From Warsaw’s perspective, what was happening with real reserves is key. In 2022, there were over 20 million unused vaccines in the warehouses of the Government Strategic Reserve Agency. The Ministry of Health’s logic was simple: accepting further batches would mean the new preparations would have to be thrown away.
Force Majeure Argument
The main pillar of Poland’s defense will be the argument of “force majeure,” linked to the war in Ukraine. The logic is that Russian aggression forced the immediate mobilization of the state’s finances and resources, and spending billions of zloty on preparations known to be unused was unjustified.
It is precisely on this field that the toughest part of the dispute will unfold: the court will assess whether the war and its consequences meet the criteria of force majeure under Belgian law, and whether there is a sufficient link between this event and the non-performance of contractual obligations.
Financial Risk and Possible Scenarios
The case is based on Belgian law, which has not only formal but also tactical significance. Lawyers representing Poland pointed out that the proceedings should be evaluated according to Belgian substantive and procedural law, as these rules were indicated in the contracts.
In this context, the financial risk associated with a possible appeal is key. If an unfavorable judgment is issued in the first instance, Poland could be obligated to make an earlier payment, putting pressure on liquidity and the budget regardless of how the process ultimately ends.
Among people analyzing the case, three realistic scenarios are circulating. The first best outcome for Poland would be the court recognizing force majeure, avoiding a billion-dollar burden and setting a precedent. The second is a settlement with Pfizer, which could limit budget risk but requires acceptable terms. The third worst scenario is defeat and the need to pay part or all of the claim, particularly problematic because previously secured funds no longer exist.
Broader Context and Regional Implications
Until 2023, money for potential compensation was secured in the COVID Fund, but the fund was liquidated in 2023 and the funds were spent on current patient treatment. This raises the stakes for Poland, facing a budget deficit balancing on the edge of agreements with the European Commission.
Besides Poland, Romania and Hungary also refused to accept further vaccine doses. Hungary has already undergone a preliminary hearing, and its lawsuit could last up to two years. Romania was also sued, and its defense strategy is coordinated with Poland.
Contract Negotiations and Pfizer’s Perspective
Poland fought for the possibility of renegotiating the contract from 2022 when it became clear there would be problems with surpluses. The European Commission was initially reluctant, but ultimately an annex was prepared that spread deliveries until 2026, reduced them by 20-30%, and allowed payment for undelivered doses.
From Pfizer’s perspective, the dispute is about money and financial predictability. COVID-19 preparations gave the company record profits and were to become a longer-term “revenue engine.” However, there is a fear of accusations of acting to the detriment of the company, and Pfizer reportedly referred to most conflictual countries as “trouble makers.”
Transparency and Parallel Legal Proceedings
The dispute over money is running parallel to a dispute over transparency. The EU Court in Luxembourg ruled that the European Commission violated transparency rules by refusing to provide SMS messages exchanged between Ursula von der Leyen and Albert Bourla.
Poland considered and took action on the criminal track in Belgium, where proceedings concern alleged irregularities in negotiations around contracts. In Belgian law, a civil court must wait for a decision from a criminal court if they are based on the same facts. Poland temporarily withdrew from the case in spring 2024 but later returned.
Future Implications
In practice, the legal consequences come down to several points: the risk of paying around 6 billion zloty without prior reserves, the possibility of paying before an appellate decision, and a precedent for EU joint purchases and relations between states and pharmaceutical manufacturers.
The last analogy among people analyzing the topic concerns Turów, where Poland paid 45 million zloty to the Czechs. Here the stakes are many times higher, and the opponent is not another EU country but a private corporation.